全文获取类型
收费全文 | 1172篇 |
免费 | 172篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 98篇 |
妇产科学 | 15篇 |
基础医学 | 123篇 |
口腔科学 | 40篇 |
临床医学 | 160篇 |
内科学 | 288篇 |
皮肤病学 | 13篇 |
神经病学 | 63篇 |
特种医学 | 168篇 |
外科学 | 148篇 |
综合类 | 36篇 |
预防医学 | 63篇 |
眼科学 | 14篇 |
药学 | 39篇 |
中国医学 | 5篇 |
肿瘤学 | 58篇 |
出版年
2022年 | 5篇 |
2021年 | 15篇 |
2020年 | 11篇 |
2019年 | 15篇 |
2018年 | 43篇 |
2017年 | 49篇 |
2016年 | 42篇 |
2015年 | 45篇 |
2014年 | 41篇 |
2013年 | 68篇 |
2012年 | 44篇 |
2011年 | 37篇 |
2010年 | 69篇 |
2009年 | 56篇 |
2008年 | 33篇 |
2007年 | 31篇 |
2006年 | 24篇 |
2005年 | 23篇 |
2004年 | 21篇 |
2003年 | 23篇 |
2002年 | 24篇 |
2001年 | 27篇 |
2000年 | 18篇 |
1999年 | 12篇 |
1998年 | 61篇 |
1997年 | 56篇 |
1996年 | 55篇 |
1995年 | 49篇 |
1994年 | 32篇 |
1993年 | 42篇 |
1992年 | 24篇 |
1991年 | 25篇 |
1990年 | 23篇 |
1989年 | 17篇 |
1988年 | 28篇 |
1987年 | 25篇 |
1986年 | 17篇 |
1985年 | 17篇 |
1984年 | 15篇 |
1983年 | 17篇 |
1982年 | 6篇 |
1981年 | 16篇 |
1980年 | 8篇 |
1978年 | 4篇 |
1977年 | 11篇 |
1976年 | 9篇 |
1975年 | 3篇 |
1968年 | 2篇 |
1938年 | 3篇 |
1936年 | 2篇 |
排序方式: 共有1354条查询结果,搜索用时 0 毫秒
51.
52.
Kenichi Tsujita MD PhD Akiko Maehara MD Gary S. Mintz MD Hiroshi Doi MD PhD Takashi Kubo MD PhD Celia Castellanos MD Jian Liu MD Junqing Yang MD Carlos Oviedo MD Theresa Franklin-Bond MS PA Neil Dasgupta MA Sinan Biro BS Lokesh Dani BA George D. Dangas MD PhD Roxana Mehran MD Ajay J. Kirtane MD Alexandra J. Lansky MD Edward M. Kreps MD Michael B. Collins MD Gregg W. Stone MD Jeffrey W. Moses MD Martin B. Leon MD 《The American journal of cardiology》2008,102(12):1608-1613
53.
The color complementation assay (CCA) is a method of allele-specific DNA amplification by which competitive priming and extension of fluorescently labeled oligonucleotide primers determine the color of DNA amplification product. This diagnostic method precludes the need for radioisotopes, electrophoresis, and multiple high-stringency reaction conditions. The multiplicity of mutant globin genes present in Southeast Asians complicates clinical diagnosis and underscores the importance of DNA-based diagnostic methods. We have applied CCA to distinguish beta A and beta E alleles. Competing 15mer primers were a fluorescein-labeled complement to beta A and a rhodamine-labeled complement to beta E, identical except for their central nucleotides. A common unlabeled primer was used to amplify DNA product, the color of which was determined by the perfectly complementary primer. Color photography and spectrofluorometry, as well as a method of black-white photography that we developed to distinguish fluorescein- and rhodamine- labeled DNA, were used to record results. We applied CCA to define the complex genotype of a Thai woman with thalassemia intermedia, 96% HbE, and 4% HbF whose possible genotypes included several permutations of alpha-thalassemia, beta-thalassemia, and beta E genes. zeta-Globin gene mapping of DNA doubly digested with Bg/II and Asp 718 showed the -alpha 3.7/--SEA genotype, and CCA confirmed homozygous beta E/beta E. The CCA is useful for diagnosing the compound hemoglobin genotypes of Southeast Asians and could be applied also to prenatal diagnosis in this population. 相似文献
54.
Dr. Robert J. Stratta MD Mark S. Shaeffer PharmD Rodney S. Markin MD PhD R. Patrick Wood MD Alan N. Langnas DO Elizabeth C. Reed MD Jeremiah P. Donovan MD Gail L. Woods MD Kathleen A. Bradshaw RN Todd J. Pillen PA Byers W. Shaw Jr. MD 《Digestive diseases and sciences》1992,37(5):673-688
Cytomegalovirus is the single most important pathogen in clinical transplantation. Although much progress has been made in our understanding of the molecular biology and epidemiology of CMV infection and in our ability to diagnosis and treat CMV disease, it remains a major cause of morbidity but is no longer a major cause of mortality after liver transplantation. Risk factors for CMV disease after liver transplantation include donor and recipient serologic status, the use of antilymphocyte therapy, and retransplantation. CMV disease occurs early after transplantation, and the most frequent site of disease is the hepatic allograft. We have treated 79 patients with intravenous ganciclovir, with ultimate control of disease achieved in 69 patients (87.3%). Preliminary results using intravenous immunoglobulin and oral acyclovir for CMV prophylaxis in high-risk patients have been encouraging. In addition to producing clinical syndromes, CMV may have direct immunologic effects and is a marker of the net state of immunosuppression. 相似文献
55.
The vagus nerve,recurrent laryngeal nerve,and external branch of the superior laryngeal nerve have unique latencies allowing for intraoperative documentation of intact neural function during thyroid surgery 下载免费PDF全文
56.
Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients 总被引:18,自引:0,他引:18
Braunstahl GJ Kleinjan A Overbeek SE Prins JB Hoogsteden HC Fokkens WJ 《American journal of respiratory and critical care medicine》2000,161(6):2051-2057
Allergic rhinitis and asthma often coexist and share a genetic background. Pathophysiologic connections between the nose and lungs are still not entirely understood. This study was undertaken to compare allergic inflammation and clinical findings in the upper and lower airways after segmental bronchial provocation (SBP) in nonasthmatic allergic rhinitis patients. Eight nonasthmatic, grass pollen-sensitive patients with allergic rhinitis and eight healthy controls were included. Bronchial biopsies and blood samples were taken before (T(0)) and 24 h (T(24)) after SBP. Nasal biopsies were obtained at T(0), 1 h after SBP (T(1)), and T(24). Immunohistochemical staining was performed for eosinophils (BMK13), interleukin (IL)-5, and eotaxin. The number of eosinophils increased in the challenged and unchallenged bronchial mucosa (p < 0.05) and in the blood (p = 0.03) of atopic subjects at T(24). We detected an increase of BMK13-positive and eotaxin-positive cells in the nasal lamina propria and enhanced expression of IL-5 in the nasal epithelium of atopic subjects only at T(24) (p < 0.05). SBP induced nasal and bronchial symptoms as well as reductions in pulmonary and nasal function in the allergic group. No significant changes could be observed in healthy controls. The study shows that SBP in nonasthmatic allergic rhinitis patients results in peripheral blood eosinophilia, and that SBP can induce allergic inflammation in the nose. 相似文献
57.
Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia 总被引:4,自引:0,他引:4
Foon KA; Schroff RW; Bunn PA; Mayer D; Abrams PG; Fer M; Ochs J; Bottino GC; Sherwin SA; Carlo DJ 《Blood》1984,64(5):1085-1093
A phase I clinical trial was initiated to treat patients with stage IV B-derived chronic lymphocytic leukemia (CLL) with the IgG2a murine monoclonal antibody T101. This antibody binds to a 65,000-mol wt (T65) antigen found on normal T lymphocytes, malignant T lymphocytes, and B- derived CLL cells. All of the patients had a histologically confirmed diagnosis of advanced B-derived CLL and were refractory to standard therapy, and more than 50% of their leukemia cells reacted with the T101 antibody in vitro. The patients received T101 antibody two times per week, over two to 50 hours by intravenous administration in 100 mL of normal saline containing 5% human albumin. Twelve patients were treated with a fixed dosage of 1, 10, 50, or 100 mg, and one patient was treated with 140 mg of antibody. It was demonstrated that patients given two-hour infusions of 50 mg developed pulmonary toxicity, with shortness of breath and chest tightness. This toxicity was eliminated when infusions of 50 or 100 mg of T101 were prolonged to 50 hours. All dose levels caused a rapid but transient decrease in circulating leukemia cell counts. In vivo binding to circulating and bone marrow leukemia cells was demonstrated at all dose levels with increased binding at higher dosages. Antimurine antibody responses were not demonstrated in any patients at any time during treatment. Circulating free murine antibody was demonstrated in the serum of only the two patients treated with 100 mg of antibody as a 50-hour infusion and the patient treated with 140 mg of antibody over 30 hours. Antigenic modulation was demonstrated in patients treated at all dose levels but was particularly apparent in patients treated with prolonged infusions of 50 and 100 mg of antibody. We were also able to demonstrate antigenic modulation in lymph node cells, which strongly suggests in vivo labeling of these cells. Overall, T101 antibody alone appears to have a very limited therapeutic value for patients with CLL. The observations of in vivo labeling of tumor cells, antigenic modulation, antibody pharmacokinetics, toxicity, and antimurine antibody formation may be used in the future for more effective therapy when drugs or toxins are conjugated to the antibody. 相似文献
58.
59.
60.
Overbeek Kasper A. Cahen Djuna L. Kamps Anne Konings Ingrid C. A. W. Harinck Femme Kuenen Marianne A. Koerkamp Bas Groot Besselink Marc G. van Eijck Casper H. Wagner Anja Ausems Margreet G. E. van der Vlugt Manon Fockens Paul Vleggaar Frank P. Poley Jan-Werner van Hooft Jeanin E. Bleiker Eveline M. A. Bruno Marco J. 《Familial cancer》2020,19(3):247-258
Familial Cancer - In high-risk individuals participating in a pancreatic cancer surveillance program, worrisome features warrant for intensified surveillance or, occasionally, surgery. Our... 相似文献